Recursion Jun 5, 2026 Recursion Pharma director Christopher Gibson sells $144,800 in stock - Investing.com
Recursion Jun 5, 2026 Recursion Pharma director Christopher Gibson sells $144,800 in stock - Investing.com
Recursion Jun 4, 2026 Recursion Pharmaceuticals Stock (RXRX) Opinions on Clinical Proof and AI Platform Advancements - Quiver Quantitative
Recursion Jun 2, 2026 Recursion vs. Schrodinger: Comparing Biotech and Software Drug Discovery Strategies in 2026 - News and Statistics - IndexBox
Recursion Jun 2, 2026 A Look At Recursion Pharmaceuticals (RXRX) Valuation As Shares Show Short Term Momentum - simplywall.st
Recursion May 21, 2026 Can Altitude Lab’s Early Wins Reframe Recursion Pharmaceuticals’ (RXRX) High-Burn Platform Bet? - Sahm
Recursion May 20, 2026 Can Altitude Lab’s Early Wins Reframe Recursion Pharmaceuticals’ (RXRX) High-Burn Platform Bet? - simplywall.st
Recursion May 10, 2026 A Look At Recursion Pharmaceuticals (RXRX) Valuation After Recent Clinical And Cost Management Updates - simplywall.st
Recursion May 9, 2026 A Look At Recursion Pharmaceuticals (RXRX) Valuation After Clinical Updates And FDA Discussions - Yahoo Finance
Recursion May 8, 2026 Recursion Milestones Link AI Discovery To Clinical And Valuation Upside - Yahoo Finance
Recursion May 8, 2026 Recursion’s AI Drug Programs Show Early Clinical Progress And Valuation Gap - simplywall.st
Recursion May 6, 2026 After a decade of hype, Najat Khan is bringing Recursion back down to earth - Fierce Biotech
Recursion May 6, 2026 Recursion Pharmaceuticals Stock (RXRX) Opinions on Q1 2026 Earnings - Quiver Quantitative
Recursion May 6, 2026 Recursion Reports First Quarter Financial Results and Provides Business Update - markets.businessinsider.com
Recursion Apr 29, 2026 Recursion to Report First Quarter 2026 Business Updates and Financial Results on May 6 - The Manila Times